Advertisement
Singapore markets close in 7 hours 18 minutes
  • Straits Times Index

    3,256.82
    -36.31 (-1.10%)
     
  • Nikkei

    37,880.73
    -579.35 (-1.51%)
     
  • Hang Seng

    17,144.12
    -57.15 (-0.33%)
     
  • FTSE 100

    8,040.38
    -4.43 (-0.06%)
     
  • Bitcoin USD

    64,375.03
    -2,415.82 (-3.62%)
     
  • CMC Crypto 200

    1,394.54
    -29.56 (-2.08%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • Dow

    38,460.92
    -42.77 (-0.11%)
     
  • Nasdaq

    15,712.75
    +16.11 (+0.10%)
     
  • Gold

    2,330.00
    -8.40 (-0.36%)
     
  • Crude Oil

    82.73
    -0.08 (-0.10%)
     
  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     
  • FTSE Bursa Malaysia

    1,571.67
    +0.19 (+0.01%)
     
  • Jakarta Composite Index

    7,174.53
    -7,110.81 (-49.78%)
     
  • PSE Index

    6,572.75
    0.00 (0.00%)
     

Is Gilead Sciences a Buy After Its Disappointing Q2 Results?

Is Gilead Sciences a Buy After Its Disappointing Q2 Results?

Gilead Sciences (NASDAQ: GILD) beat Wall Street estimates when the big biotech announced its first-quarter results in late April. Last week, Gilead announced second-quarter results that were below analysts' expectations. Gilead has been in the news quite a bit in recent months thanks to the clinical success for its COVID-19 therapy remdesivir.